United Kingdom National Register Study of Anti-Epileptic Medications: Suspected Foetal Congenital And Pregnancy-Associated Side Effects

Benjamin Phillips¹, Ismay Evans,¹ Victoria Skerrett,² and Alan M. Jones^{1*}

- ¹ School of Pharmacy, University of Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom.
- ² School of Nursing and Midwifery, University of Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom.
- * Corresponding author: <u>a.m.jones.2@bham.ac.uk;</u> +44(0)121-414-2788; ORCID: <u>https://orcid.org/0000-0002-3897-5626</u>

Keywords: Adverse drug reaction, valproic acid, lamotrigine, topiramate, levetiracetam, foetal, congenital, pregnancy, epilepsy, side effect, histone hyperacetylation, teratogenic, neural tube defect, histone deacetylase, sodium valproate

Abstract

Objective There continue to be concerns regarding exposure during pregnancy to antiepilepsy drugs (AEDs). The study aims were to determine the suspected adverse drug reactions (ADRs) associated with AEDs and potential mechanistic hypotheses.

Methods Suspected ADR profiles for 8 AEDs were data-mined from the MHRA Yellow Card scheme (January 2018-August 2022) together with prescribing data from OpenPrescribing (August 2017-July 2022). The physicochemical, pharmacokinetic, and pharmacology of the AEDs were data-mined from public databases.

Results The suspected ADRs per 1,000,000 R_x identified across all AEDs are statistically significant (χ^2 test, P < .05). Pregnancy, puerperium & perinatal conditions associated with lamotrigine (1.51 per 1,000,000 R_x , χ^2 test, P < .05, d = 2.720, 95% CI [1.656, 4.469]) had a larger size effect than valproic acid (2.28 per 1,000,000 R_x , χ^2 test, P < .05, d = 1.846, 95% CI [1.150, 2.964]). The large size effect associated with valproic acid for congenital and hereditary disorders (d = 9.069, 95% CI [5.807, 14.163]) and foetal exposure during pregnancy (d = 6.632, 95% CI [4.894, 8.988]) were notable amongst the AEDs. Valproic acid, a known teratogen, had the unique and clinically achievable targeting of histone deacetylase (HDAC 1 IC₅₀ = 54.4, HDAC2 IC₅₀ = 82.4 micromolar, HDAC3 IC₅₀ = 148 micromolar, HDAC8 IC₅₀ = 144 micromolar, $C_{max} = 184.3$ micromolar) associated with teratogenicity.

Significance There is renewed discussion about the management of epilepsy in pregnancy, and the risks of different AEDs. Whilst 1 in 250 women have epilepsy, they account for 1 in 10 of women who die in childbirth or postpartum. Fears about ADRs impact on adherence to medication, whilst pregnancy itself reduces the serum level of AEDs. As a result of this women are at increased risk of seizures during pregnancy and childbirth. There has been a doubling of Sudden and Unexpected Death in Epilepsy (SUDEP) in mothers between 2013-2015 and 2019-2021 in the UK and Ireland. The AEDs studied have diverse modes of action, and the UNITED STATED STA

effect than valproic acid (d = 2.720 vs 1.846) for suspected pregnancy, puerperium and perinatal ADRs. As noted in other studies, there is a suspected association between valproic acid exposure and 1) congenital and hereditary disorders (d = 9.069), and 2) foetal exposure during pregnancy (d = 6.632) compared to other studied AEDs. Pregnancy-related ADRs with levetiracetam and topiramate did not reach statistical significance, however neurological ADRs in children who were exposed to lamotrigine and levetiracetam continue to be the subject of scrutiny.

Key Points:

- 1. There are ongoing concerns regarding exposure to all anti-epilepsy drugs (AEDs) during pregnancy. Poor seizure control in pregnancy is a cause of maternal death, valproic acid continues to be used by women despite it being a known teratogen, and other AEDs also carry risks of significant ADRs.
- 2. AEDs have diverse modes of action, and the unique polypharmacology of AEDs influences their ADR profiles.
- 3. Lamotrigine had a larger size effect than valproic acid (d = 2.720 vs 1.846) for suspected pregnancy, puerperium and perinatal ADRs.
- 4. There is a strong association between valproic acid exposure and congenital and hereditary disorders including foetal valproate spectrum disorder (FVSD), autism spectrum disorder (ASD), spina bifida, polydactyly and cleft palate (d = 9.069).
- 5. There is an association between valproic acid and foetal exposure during pregnancy (d = 6.632).

Introduction

Adverse drug reactions (ADRs) are unintended responses to a drug, causing 1 in 6 hospital admissions, at a cost to the NHS of approx. £2.2 Bn p.a., increasing duration of hospital stays, contributing to poor adherence, and adversely affecting quality of life.[1]

Epilepsy affects 1 in 103 people globally.[2] Anti-epileptic drugs (AEDs) control seizure activity in 70% of patients but can also cause adverse drug reactions (ADRs).[2] AEDs prescribed in the United Kingdom include valproic acid, carbamazepine, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, topiramate and zonisamide (**Figure S1**).

Over 2,500 women who suffer from epilepsy become pregnant each year in the UK [3] and the prescribing of AEDs in pregnancy is a cause for concern as many of them have teratogenic effects. *In-utero* AED exposure increases the risk of a physical birth abnormality, harms growth and development.[3] Women with epilepsy are ten times more likely to die during pregnancy and the risks to the developing foetus need to be balanced against the risk to both mother and baby of severe seizures.[3-4]

Sodium valproate is a known teratogen, and a drug of concern for many decades, being first linked to increased risks of congenital and developmental disorders in 1972.[5]. Subsequent studies led to teratogenic risk warnings to be added to valproic acid.[6] Currently 1,800 women of child-bearing age take valproic acid despite the Pregnancy Prevent

Programme (PPP) being in place since 2018.[7] In-utero exposure can cause foetal valproate syndrome, which increases the risk of congenital and neurodevelopmental disorders, and approximately 20,000 babies in the UK have been affected.[8] 40 in 100 babies exposed to valproic acid *in-utero* have neurodevelopmental disorders.[9-10] Valproic acid has the highest risk of congenital malformations, including spina bifida, affecting over 10 in 100 babies.[8] Valproic acid's *in-utero* effects are dose dependent, with higher doses increasing risks of congenital or developmental disorders.[11]

The prescription of valproic acid to women of childbearing potential is now accompanied by a Pregnancy Prevention Programme (PPP). [12-14] Through this, the use of sodium valproate in pregnancy has seen a significant decline;[15] however, it is still used in pregnancy. Despite a high-profile safety review,[16] medication warnings and messages to professionals, many pregnant women with epilepsy have not had the opportunity to discuss valproate with a specialist. A survey by three UK epilepsy charities found that nearly 20% of women prescribed valproate reported they were not aware of the risks of the drug, and that only 41% had signed up to the PPP.[15]

Valproic acid is the most effective medication for tonic-clonic seizures[17] which impacts on prescribing choices. Focal epilepsy can be effectively managed with alternative AEDs, however there are concerns about the ADR profiles of alternatives to valproic acid. Lamotrigine and levetiracetam are considered the safest AEDs.[3] However, levetiracetam and lamotrigine are drugs named for additional scrutiny for neurodevelopmental ADRs in children exposed in utero in the EMPiRE project [18] Topiramate and carbamazepine are high risk and cause physical defects in 4-5 per 100 babies compared to 2-3 in 100 in the general population.[3] Bjørk MH, et al[19] showed topiramate and valproic acid increase risks of autism spectrum disorder (ASD) and neurodevelopmental disorders, initiating a safety alert review into topiramate in the UK.

Belete et al.[20] found evidence of an association between AED exposure (carbamazepine, lamotrigine, levetiracetam, and valproic acid) and incident Parkinson disease using data from the UK Biobank. This wide range of ADRs across all the AEDs, with very significant consequences for mothers and their children, suggests a combinatorial data-driven assessment of AED polypharmacology and ADR profiles [21-26], is timely.

Methods

Prescribing Data

NHS (England) primary care prescribing data (August 2017-July 2022 inclusive) for the generic product form was obtained from the OpenPrescribing database https://openprescribing.net/ on 13.10.2022.

Suspected Adverse Drug Reactions

Suspected ADR data was extracted from the MHRA Yellow Card database https://yellowcard.mhra.gov.uk/idaps (January 2018-August 2022 inclusive on 15.10.2022). A lag time of 5-months between reaction and report was factored into the data. AEDs that did not meet the inclusion criteria (**Table S1**) were removed (**Table S2**).

Data were collected for the number of suspected ADRs and stratified by organ class and fatalities. Significant suspected ADRs were found by MedDRA organ class with > 100 total reactions in \geq 1 AED studied or statistical significance (p < .05, χ^2) across the AEDs studied. Pregnancy was included despite low suspected ADR reports and did not show statistical significance (P = .655, χ^2) for an important research comparison.

ADR Data were standardised per 1,000,000 prescriptions to enable comparisons uninfluenced by prescribing variation (**Equation S1**).

Chemical Properties

Physiochemical and pharmacokinetic properties

AED properties were determined from the summary of product characteristics (SPC) accessed through the Electronic Medicines Compendium (EMC) and the manually curated database of bioactive molecules with drug-like properties of the European Molecular Biology Laboratory (ChEMBL) https://www.ebi.ac.uk/chembl/.

To calculate parameters:

The $-\log_{10}$ of the half-maximal inhibitory concentration (plC_{50}) was gathered for the main human target protein of each AED using the formula $-log_{10}(IC_{50})$.

Lipophilic Ligand Efficacy (LLE) was found through $pIC_{50} - clog_{10}P$, with $cLog_{10}P$ the calculated partition coefficient between lipid (n-octanol) and the aqueous phase. LLE values (<5) correlate to increased off-target drug-protein interactions and an increased risk of toxicity.[27]

Peak serum concentration of the drug (C_{max}) values was gathered from either the SPC and/or FDA monographs and converted to nM.

Target Affinity

Each AED's target affinity was obtained via the IC₅₀ between the AED and single human protein target from the ChEMBL database and relevant literature (accessed 06.11.2022). AEDs with multiple IC₅₀ values for the same target were standardised to the median to give a relative affinity and compensate for outliers.

Statistical Analysis

Chi-Squared tests (χ^2) were performed on standardised ADR data to find statistical significance (p < .05, χ^2) using Microsoft Excel. Where Pearsons χ^2 tests were performed on n < 5, Yates's correction was employed to avoid the assumption of continuous distribution of binary data.

Odds Ratio (*d*) and confidence intervals [CI] were calculated using **Equation S2**. This method was employed to find within the 8 AEDs which, if any, have a significantly higher risk of a particular ADR compared to other AEDs. An alternative approach to detect a "true" signal by comparison of a particular ADR against all UK-licensed drugs was outside the scope of this

study. It should also be noted that **Table S3** contains >2000 two-way comparisons between pairs of AEDs, of which > 300 have P < .05. Purely by chance ~100 of these pairs would have a P < .05. Thus, additional odds risk ratio (*d*) and confidence interval (CI) statistical evaluation was performed on the most significant findings to determine CI >1 not \geq 1 to avoid bias. Calculations were completed using Microsoft Excel and displayed as odds-ratio plots.

Ethics Approval

All data used in this study was publicly available, with no identifiable patient information, and was exempt from ethics approval. Prepublication of a protocol for this study was not required based on the above ethical considerations.

Results

Physiochemical and Pharmacokinetic Properties

Table S4 holds a summary of the main AED properties and gives a reference dataset to the drug concentrations that would have been likely to have affected the targets studied.

Target Affinity

Table 1. Selectivity profiles of the 8 AED's based on human single protein targets and standardised as median IC₅₀ values (μM)

| | Valproic | Carbamazepine | Gabapentin | Lamotrigine | Levetiracetam | Oxcarbazepine | Topiramate | Zonisamide |
|------------------------|----------|---------------|------------|-------------|---------------|---------------|------------|------------|
| | Acid | _ | _ | | | _ | - | |
| Leukotriene A4 | 10 | | | | | | | |
| Hydrolase | | | | | | | | |
| Unspecified Histone | | | | | PBA: 2250 | | 2200 | |
| Deacetylase Class | | | | | | | | |
| Histone Deacetylase 1 | 54.4 | | | | | | | |
| Histone Deacetylase 2 | 82.4 | | | | | | | |
| Histone Deacetylase 3 | 147.8 | 2 | | | | | | |
| Histone Deacetylase 4 | 200 | | | | | | | |
| Histone Deacetylase 5 | 2000 | | | | | | | |
| Histone Deacetylase 6 | 1108 | | | | | | | |
| Histone Deacetylase 7 | 2000 | 2 | | | | | | |
| Histone Deacetylase 8 | 143.7 | | | | | | | |
| Histone Deacetylase 9 | 2000 | | | | | | | |
| NAD-Dependent | 100 | | | | | | | |
| protein deacylase | | | | | | | | |
| sirtuin-5 | | | | | | | | |
| Coagulation Factor III | 1750 | | | | | | | |
| Aldehyde Reductase | 50.1 | | | | | | | |
| Bile Salt Export Pump | 1000 | 711 | 1000 | 133 | 566.5 | 133 | 566.5 | 134 |
| Canaliaular | | 100 | | | 122 | 133 | 133 | 122 |
| Canalicular | | 133 | | | 133 | 133 | 133 | 133 |
| multispecific organic | | | | | | | | |
| anion transporter 1 | | | | | | | | |

| Canalicular multispecific organic anion transporter 2 | 133 | | | 133 | 133 | 133 | 133 |
|---|-------|-------|-------|-----|-----|-----|-----|
| Multidrug resistance- associated protein 4 | 133 | | | 133 | 133 | 133 | 133 |
| Cytochrome P450 2J2 | 50 | | | | | | |
| Cytochrome P450 3A4 | 10 | | | | | | |
| P2X purinoceptor 4 | 100 | | | | | | |
| HERG | 104.7 | | 282.4 | | | | |
| Voltage gated L-type calcium channel alpha- 1c subunit | | | 1422 | | | | |
| Voltage-gated calcium channel alpha2/delta subunit 1 | | 0.027 | | | | | |
| Sodium channel protein type II alpha subunit | | | 42.3 | | | | |
| Sodium channel protein type III alpha subunit | | | 17 | | | | |
| Sodium channel protein type V alpha subunit | | | 67.3 | | | | |
| Sodium channel protein type IX alpha subunit | 22 | | 17 | | | | |

| Sodium channel | | | | 97 | | | | |
|-----------------------|-------|-----------|------|------|-------|------|------|-------|
| protein type X alpha | | | | | | | | |
| subunit | | | | | | | | |
| Polyadenylate-binding | | | | | | 47.1 | | |
| protein 1 | | | | | | | | |
| P2X purinoceptor 4 | | | | | | 10 | | |
| Carbonic anhydrase I | | | | | | | 0.25 | |
| Carbonic anhydrase II | | | | | | | 0.87 | 0.035 |
| Carbonic anhydrase V | | | | | | | | 0.021 |
| Specific Ion Channel | | 18 | | | | | | |
| (Potassium) | | | | | | | | |
| C _{max} (µM) | 184.3 | 11.0-14.8 | 23.5 | 18.0 | 123.4 | 34.0 | 4.4 | 9.4 |

| 0.001-0.01 μM |
|---------------|
| 0.01-0.1 μM |
| 0.1-1 μM |
| 1-10 µM |
| 10-100 μM |
| >100 µM |
| Undetermined |

PBA = Levetiracetam major metabolite (2-pyrrolidinone-*n*-butyric acid)

Not all interactions are physiologically achievable. The C_{max} of each AED is provided to enable a working control to short-term physiological relevance.

It should be noted that the C_{max} , measured as total (bound and unbound) plasma concentration (usually after a single dose), and primarily related to the volume of distribution of total drug, is a good surrogate for the tissue concentrations likely to be achieved during short-term therapy. However, during long-term therapy, and factoring in interactions on the pharmacological targets, the C_{max} is likely to drift higher due to bioaccumulation.

Valproic acid's main target is histone deacetylases (HDAC) 1-9 (**Table 1**) each HDAC isozyme responsible for different developmental disorders.[28]

Valproic acid teratogenic effect has been well known since 2001 [29-32] A cumulative metaanalysis of clinical trials by Tanoshima et al provides further confirmatory evidence of the link between valproic acid and teratogenicity.[33]

Valproic acid (HDAC1 IC $_{50}$ = 54.4 µM, HDAC2 IC $_{50}$ = 82.4 µM, HDAC3 IC $_{50}$ = 147.8 µM, HDAC4 IC $_{50}$ = 200 µM, HDAC5 IC $_{50}$ = 2,000 µM, HDAC6 IC $_{50}$ = 1,108 µM, HDAC7 IC $_{50}$ = 2,000 µM, HDAC8 IC $_{50}$ = 143.7 µM, and HDAC9 IC $_{50}$ = 2,000 µM), carbamazepine (HDAC3 IC $_{50}$ = 2 µM, HDAC7 IC $_{50}$ = 2 µM), topiramate (unspecified HDAC IC $_{50}$ = 2,200 µM), and levetiracetam's active metabolite, 2-pyrrolidinone-*n*-butyic acid [PBA] (unspecified HDAC 2,25 µM) inhibit HDAC family members implicated in foetal defects. Only carbamazepine's inhibition of HDAC3 and 7 (C_{max} = 11-14.8 µM) and valproic acid's inhibition of HDAC1, 2, 3, and 8 (C_{max} = 184.3 µM) are clinically achievable.

All AEDs displayed unique pharmacological profiles. Valproic acid was the least selective, with fourteen protein target interactions compared to gabapentin's two. Levetiracetam displayed no biologically relevant inhibition at any off target. All AEDs interact with bile salt export pump (BSEP), but no clinically significant inhibition occurs. Valproic acid ($C_{max} = 184.3 \,\mu\text{M}$) also had biological achievable inhibition of Leukotriene A4 Hydrolase ($IC_{50} = 10 \,\mu\text{M}$) and NAD-dependent protein deacylase sirtuin ($IC_{50} = 100 \,\mu\text{M}$).

ADRs

Table 2. Summary of the reported suspected adverse drug reactions within the UK for all 8 studied AEDs. The number in parentheses represents the reported ADRs per 1,000,000 prescriptions as a standardised value for comparison. *P*-values were calculated through chi-squared analysis on the standardised data values. Key: Further details can be found in ^a **Chart S1**; ^b **Chart S2**; ^c **Chart S3** and **Figures S2-S9**.

| | Valproic acid | Carbamazepine | Gabapentin | Lamotrigine | Levetiracetam | Oxcarbazepine | Topiramate | Zonisamide | <i>P</i> -value |
|----------------------------------|---------------|---------------|--------------|---------------|---------------|---------------|---------------|--------------|-----------------|
| OVERALL ADR DATA | | | | | | | | | |
| Total Prescriptions ^a | 12285032 | 11162013 | 36692340 | 15233924 | 12323387 | 548366 | 4975166 | 841291 | - |
| Total ADR Reactions ^b | 3045 (247.86) | 1818 (162.87) | 2291 (62.44) | 1754 (115.14) | 1680 (136.33) | 216 (393.90) | 1027 (206.43) | 209 (248.43) | <0.05 |
| Fatalities ^c | 31 (2.52) | 9 (0.81) | 35 (0.95) | 17 (1.12) | 26 (2.11) | 0 (0) | 3 (0.60) | 3 (3.57) | 0.470 |
| Serious (Excl. Fatalities) | 748 (60.89) | 484 (43.36) | 568 (15.94) | 464 (30.46) | 482 (39.11) | 70 (127.65) | 241 (48.44) | 60 (71.32) | <0.05 |
| MAIN PREGNANCY RELATED | O ADRs | | | | | | | | |
| Congenital, Familial & Geneti | c Disorders | | | | | | | | |
| Total ADRs | 178 (14.49) | 18 (1.61) | 0 (0) | 34 (2.23) | 23 (1.87) | 1 (1.82) | 8 (1.61) | 2 (2.38) | <0.05 |
| Fatalities | 4 (0.33) | 0 (0) | 0 (0) | 2 (0.13) | 1 (0.08) | 0 (0) | 0 (0) | 1 (1.19) | <0.05 |
| Congenital and Hereditary | | | | | | | | | |
| Disorders | 78 (6.35) | 3 (0.27) | 0 (0) | 8 (0.53) | 10 (0.81) | 0 (0) | 5 (1.00) | 0 (0) | <0.05 |
| Foetal anticonvulsant | | | | | | | | | |
| syndrome | 63 (5.13) | 3 (0.27) | 0 (0) | 2 (0.13) | 2 (0.16) | 0 (0) | 0 (0) | 0 (0) | <0.05 |
| Congenital Anomaly | 13 (1.06) | 0 (0) | 0 (0) | 4 (0.26) | 5 (0.41) | 0 (0) | 5 (1.00) | 0 (0) | 0.756 |
| Multiple congenital | | | | | | | | | |
| abnormalities | 1 (0.08) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0.999 |
| Teratogenicity | 1 (0.08) | 0 (0) | 0 (0) | 1 (0.07) | 2 (0.16) | 0 (0) | 0 (0) | 0 (0) | 0.999 |
| Gastrointestinal Tract | | | | | | | | | 0.938 |
| Disorders | 7 (0.57) | 0 (0) | 0 (0) | 3 (0.20) | 2 (0.16) | 0 (0) | 0 (0) | 0 (0) | |
| Congenital Inguina Hernia | 2 (0.16) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | <0.05 |
| Cleft Palate | 5 (0.41) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0.894 |
| Musculoskeletal and | | | | | | | | | 0.150 |
| connective tissue disorders | | | | | | | | | |
| congenital | 34 (2.77) | 8 (0.72) | 0 (0) | 6 (0.39) | 5 (0.41) | 0 (0) | 1 (0.20) | 0 (0) | |
| Dysmorphism | 10 (0.81) | 3 (0.27) | 0 (0) | 2 (0.13) | 2 (0.16) | 0 (0) | 0 (0) | 0 (0) | 0.867 |

| Musculoskeletal and | | | | | | | | | |
|--------------------------------|------------------|-------------|------------|------------|-------------|------------|-------------|------------|-------|
| connective tissue disorders of | | | | | | | | | |
| limbs congenital | 13 (1.06) | 4 (0.36) | 0 (0) | 4 (0.26) | 2 (0.16) | 0 (0) | 1 (0.20) | 0 (0) | 0.854 |
| Neurological Disorders | | | | | | | | | |
| congenital | 21 (1.71) | 3 (0.27) | 0 (0) | 5 (0.33) | 0 (0) | 1 (1.82) | 0 (0) | 2 (2.38) | 0.300 |
| Spina Bifida | 7 (0.57) | 0 (0) | 0 (0) | 1 (0.07) | 0 (0) | 0 (0) | 0 (0) | 1 (1.19) | 0.567 |
| Cerebral Palsy | 9 (0.73) | 1 (0.09) | 0 (0) | 0 (0) | 0 (0) | 1 (1.82) | 0 (0) | 0 (0) | 0.247 |
| Injury, Poisoning & Procedure | al Complications | s: | | | | | | | |
| Total ADRs: | 389 (31.66) | 180 (16.13) | 162 (4.42) | 129 (8.47) | 155 (12.58) | 19 (34.65) | 71 (14.27) | 10 (11.89) | <0.05 |
| Fatalities | 2 (0.16) | 1 (0.09) | 18 (0.49) | 7 (0.46) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0.958 |
| Exposures, chemical injuries, | | | | | | | | | |
| and poisoning | 184 (14.98) | 28 (2.51) | 31 (0.84) | 49 (3.22) | 39 (3.16) | 1 (1.82) | 16 (3.22) | 1 (1.19) | <0.05 |
| Exposure in Pregnancy | 14 (1.14) | 1 (0.09) | 2 (0.05) | 5 (0.33) | 2 (0.16) | 1 (1.82) | 2 (0.40) | 0 (0) | 0.556 |
| Foetal exposure during | | | | | | | | | |
| pregnancy | 134 (10.91) | 6 (0.54) | 5 (0.14) | 22 (1.44) | 17 (1.38) | 0 (0) | 11 (2.21) | 1 (1.19) | <0.05 |
| Maternal Exposure in | | | | | | | | | 0.908 |
| Pregnancy | 5 (0.41) | 0 (0) | 1 (0.03) | 8 (0.53) | 11 (0.89) | 0 (0) | 3 (0.60) | 0 (0) | |
| Toxicity to various agents | 25 (2.03) | 17 (1.52) | 0 (0) | 11 (0.72) | 6 (0.49) | 0 (0) | 0 (0) | 0 (0) | 0.399 |
| Off Label Uses | 48 (3.91) | 12 (1.08) | 13 (0.35) | 6 (0.39) | 38 (3.08) | 4 (7.29) | 14 (2.81) | 2 (2.81) | 0.058 |
| Pregnancy, Puerperium & Per | | | | | | | | | |
| Total ADRs: | 28 (2.28) | 7 (0.63) | 1 (0.03) | 23 (1.51) | 10 (0.81) | 1 (1.82) | 3 (0.60) | 0 (0.00) | 0.655 |
| Fatalities | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | - |
| Abortions and Still Births | 13 (1.06) | 2 (0.18) | 0 (0) | 4 (0.26) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0.667 |
| Foetal Complications | 2 (0.16) | 0 (0) | 0 (0) | 2 (0.13) | 2 (0.16) | 0 (0) | 0 (0) | 0 (0) | 0.998 |
| Neonatal and Perinatal | | | | | | - 4-> | | - 4-1 | |
| Conditions | 3 (0.24) | 1 (0.09) | 1 (0.03) | 3 (0.20) | 2 (0.16) | 0 (0) | 3 (0.60) | 0 (0) | 0.977 |
| Pregnancy, Labour, Delivery | 4 (0.00) | 4 (0.00) | 0 (0) | 40 (0.70) | 4 (0.00) | 4 (4 00) | 0 (0) | 0 (0) | 0.474 |
| and Postpartum Conditions | 1 (0.08) | 4 (0.36) | 0 (0) | 12 (0.79) | 4 (0.32) | 1 (1.82) | 0 (0) | 0 (0) | 0.474 |
| OTHER SIGNIFICANT ADRS | | | | | | | | | |
| Gastrointestinal Disorders: | 105 (10 10) | 100 (10 00) | 050 (0.04) | 100 (7.00) | 0.4 (0.00) | 14 (22 22) | 100 (40 00) | T (0.00) | 1 000 |
| Total ADRs: | 165 (13.43) | 122 (10.93) | 250 (6.81) | 108 (7.09) | 84 (6.82) | 11 (20.06) | 99 (19.90) | 7 (8.32) | <0.05 |
| Fatalities | 2 (0.16) | 0 (0) | 0 (0) | 0 (0) | 1 (0.08) | 0 (0) | 0 (0) | 0 (0) | 0.997 |
| Exocrine Pancreas Conditions | 30 (2.44) | 0 (0) | 3 (0.08) | 3 (0.20) | 3 (0.24) | 0 (0) | 2 (0.40) | 0 (0) | 0.120 |
| Diarrhoea | 12 (0.98) | 8 (0.72) | 27 (0.74) | 6 (0.39) | 10 (0.81) | 1 (1.82) | 11 (2.21) | 3 (3.57) | 0.576 |
| Constipation | 7 (0.57) | 5 (0.45) | 7 (0.19) | 4 (0.26) | 1 (0.08) | 0 (0) | 4 (0.80) | 0 (0) | 0.958 |
| Nausea and Vomiting | 24 (1.95) | 27 (2.42) | 80 (2.18) | 30 (1.97) | 18 (1.46) | 8 (14.49) | 30 (6.03) | 3 (3.57) | <0.05 |

| General Disorders and Admir Total ADRs | 392 (31.91) | 238 (21.32) | 369 (10.06) | 219 (14.38) | 217 (17.61) | 35 (63.83) | 114 (22.91) | 43 (51.11) | <0.05 |
|---|-------------|-------------|-------------|-------------|-------------|------------|-------------|------------|-------|
| Fatalities | 8 (0.65) | 4 (0.36) | 7 (0.19) | 3 (0.20) | 16 (1.30) | 0 (0) | 1 (0.20) | 2 (2.38) | 0.443 |
| General Systems Disorders | 8 (0.03) | 4 (0.30) | 7 (0.19) | 3 (0.20) | 10 (1.30) | 0 (0) | 1 (0.20) | 2 (2.30) | 0.443 |
| NEC | 233 (18.97) | 130 (11.65) | 231 (6.30) | 120 (7.88) | 91 (7.38) | 14 (25.53) | 74 (14.87) | 21 (24.96) | <0.05 |
| Developmental Delay | 21 (1.71) | 1 (0.09) | 0 (0) | 0 (0) | 2 (0.16) | 0 (0) | 0 (0) | 0 (0) | 0.194 |
| Fatigue | 19 (1.55) | 18 (1.61) | 18 (0.49) | 32 (2.10) | 24 (1.95) | 4 (7.29) | 14 (2.81) | 5 (5.94) | 0.066 |
| Drug Interaction | 37 (3.01) | 19 (1.70) | 12 (0.33) | 22 (1.44) | 7 (0.57) | 4 (7.29) | 3 (0.60) | 0 (0) | <0.05 |
| Drug Ineffective | 52 (4.23) | 36 (3.23) | 39 (1.06) | 24 (1.58) | 63 (5.11) | 10 (18.24) | 16 (3.22) | 11 (13.08) | <0.05 |
| Nervous System Disorders: | - (- / | 1 2 (2 2) | 1 2 (2 2 7 | () | | | - (-) | () | |
| Total ADRs: | 577 (46.97) | 315 (28.22) | 419 (11.42) | 308 (20.22) | 359 (29.13) | 53 (96.65) | 227 (45.63) | 41 (48.73) | <0.05 |
| Fatalities: | 2 (0.16) | 1 (0.09) | 1 (0.03) | 0 (0) | 1 (0.08) | 0 (0) | 0 (0) | 0 (0) | 0.999 |
| Neurological Disorders NEC | 180 (14.65) | 149 (13.35) | 230 (6.27) | 123 (8.07) | 111 (9.01) | 14 (25.53) | 125 (25.12) | 19 (22.58) | <0.05 |
| Speech Disorder | 12 (0.98) | 6 (0.54) | 7 (0.19) | 3 (0.20) | 2 (0.16) | 0 (0) | 4 (0.80) | 1 (1.19) | 0.916 |
| Speech Disorder | , , | , , | , , | , , | , , | , , | | , , | 0.503 |
| Developmental | 13 (1.06) | 1 (0.09) | 0 (0) | 1 (0.07) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| Dyspraxia | 14 (1.14) | 0 (0) | 0 (0) | 2 (0.13) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0.433 |
| Dyslexia | 4 (0.33) | 3 (0.27) | 0 (0) | 1 (0.07) | 1 (0.08) | 0 (0) | 0 (0) | 0 (0) | 0.987 |
| Epilepsy | 39 (3.17) | 26 (2.33) | 4 (0.11) | 21 (0.11) | 23 (1.87) | 5 (9.12) | 2 (0.40) | 3 (3.57) | <0.05 |
| Seizures | 86 (7.00) | 55 (4.93) | 14 (0.38) | 43 (0.38) | 75 (6.09) | 16 (29.18) | 20 (4.02) | 1 (1.19) | <0.05 |
| Mental Impairment Disorder | 52 (4.23) | 14 (1.25) | 44 (1.20) | 36 (2.36) | 30 (2.43) | 4 (7.29) | 23 (4.62) | 4 (4.75) | 0.277 |
| Movement Disorders | 80 (6.51) | 18 (1.61) | 49 (1.34) | 25 (1.64) | 19 (1.54) | 6 (10.94) | 13 (2.61) | 2 (2.38) | <0.05 |
| Psychiatric Disorders: | | | | | | | | | |
| Total ADRs: | 345 (28.08) | 161 (14.42) | 375 (10.22) | 228 (14.97) | 299 (24.26) | 33 (60.18) | 151 (30.35) | 25 (29.72) | <0.05 |
| Fatalities: | 3 (0.24) | 1 (0.09) | 2 (0.05) | 3 (0.20) | 2 (0.16) | 0 (0) | 0 (0) | 0 (0) | 0.998 |
| Anxiety Disorders and | | | | | | | | | |
| Symptoms | 27 (2.20) | 23 (2.06) | 48 (1.31) | 34 (2.23) | 41(3.33) | 6 (10.94) | 22 (4.42) | 22 (4.75) | <0.05 |
| Cognitive and attention | | | | | | | | | |
| disorders | 53 (4.31) | 9 (0.81) | 2 (0.05) | 5 (0.33) | 2 (0.16) | 0 (0) | 1 (0.20) | 1 (1.19) | <0.05 |
| Learning Disorders | 40 (3.26) | 6 (0.54) | 0 (0) | 0 (0) | 1 (0.08) | 0 (0) | 1 (0.20) | 1 (1.19) | 0.062 |
| Attention deficit hyperactivity | | | | | | | | | 0.789 |
| disorder (ADHD) | 12 (0.98) | 2 (0.18) | 1 (0.03) | 5 (0.33) | 1 (0.08) | 0 (0) | 0 (0) | 0 (0) | |
| Autism Spectrum Disorders | | | | | | | | | |
| (ASD) | 39 (3.17) | 8 (0.72) | 0 (0) | 4 (0.26) | 4 (0.32) | 0 (0) | 0 (0) | 0 (0) | <0.05 |
| Neurodevelopmental | | 2 (2) | 2 (2) | | . (2) | - (-) | 2 (2) | . (2) | |
| Disorders | 2 (0.16) | 0 (0) | 0 (0) | 2 (0.13) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | <0.05 |

| Deliria | 30 (2.44) | 20 (1.79) | 40 (1.09) | 16 (1.05) | 19 (1.54) | 4 (7.29) | 15 (3.01) | 0 (0) | <0.05 | | |
|--|---------------|-------------|------------|-------------|------------|------------|------------|------------|-------|--|--|
| Respiratory, Thoracic and Mediastinal Disorders: | | | | | | | | | | | |
| Total ADRs: | 70 (5.70) | 67 (6.00) | 65 (1.77) | 45 (2.95) | 32 (2.60) | 1 (1.82) | 35 (7.03) | 10 (11.89) | <0.05 | | |
| Fatalities: | 1 (0.08) | 0 (0) | 3 (0.08) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0.999 | | |
| Breathing Abnormalities | 24 (1.95) | 11 (0.99) | 26 (0.71) | 14 (0.92) | 10 (0.81) | 1 (1.82) | 10 (2.01) | 5 (5.94) | 0.139 | | |
| Skin and Subcutaneous Tissu | ue Disorders: | | | | | | | | | | |
| Total ADRs: | 85 (6.92) | 235 (21.05) | 141 (3.84) | 300 (19.69) | 102 (8.28) | 12 (21.88) | 56 (11.26) | 28 (33.28) | <0.05 | | |
| Fatalities: | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | - | | |
| Rashes, eruptions and | | | | | | | | | <0.05 | | |
| exanthems NEC | 18 (1.47) | 86 (7.70) | 35 (0.95) | 108 (7.09) | 22 (1.79) | 6 (10.94) | 7 (1.41) | 4 (4.75) | | | |

Total ADRs

Gabapentin is the most prescribed AED (36,692,340 R_x) (**Table 2**). Oxcarbazepine had the most reported ADRs per million R_x (393.90), zonisamide (248.43), valproic acid (247.86), topiramate (206.43), carbamazepine (162.87), levetiracetam (136.33), lamotrigine (115.14) and gabapentin (62.44), respectively. Zonisamide had the highest suspected fatality rate (3.57 per 1,000,000 R_x) in contrast to oxcarbazepine (0). All AEDs had at least one organ system ADR which were more likely to occur with its use. Overall suspected ADRs per 1,000,000 R_x identified across all AEDs are statistically significant (χ^2 test, P < .05).

Congenital, Familial and Genetic Disorders

Valproic acid had the most suspected total ADRs in the congenital, familial, and genetic disorder category (14.49 per 1,000,000 R_x). Valproic acid had the highest standardised rate of foetal anticonvulsant syndrome (5.13 per 1,000,000 R_x). Zonisamide reported 1.19 fatalities per 1,000,000 R_x , valproic acid (0.33), lamotrigine (0.13) and levetiracetam (0.08), respectively. Congenital, familial, and genetic disorder ADRs were suspected of association with valproic acid (14.49 per 1,000,000 R_x , χ^2 test, P < .05, d = 6.432, 95% CI [4.955, 8.348]). For congenital and hereditary disorders, valproic acid was unique (d = 9.069, 95% CI [5.807, 14.163]) (**Figure 1a**).




Figure 1 (a). Odds ratio and confidence interval for congenital and hereditary disorders for all AEDs studied; and **(b)** odds ratio and confidence interval for foetal exposure during pregnancy for all AEDs studied.

Paternal route to ADRs

Table S5 shows 5 reports have been made since 1972 for children born with congenital abnormalities due to suspected exposure to VPA via the father. However, due to

transgenerational aspect of this data, it should be considered that there could be a significant degree of underreporting.

Injury, Poisoning and Procedural Complications

Oxcarbazepine had the most suspected injury, poisoning, and procedural complication ADRs $(34.65 \text{ per } 1,000,000 R_x)$, followed by valproic acid (31.66). Suspected foetal exposure during pregnancy was statistically significant across the AEDs (χ^2 , P < .05), with valproic acid reporting 10.91 per 1,000,000 R_{x} , topiramate (2.21), lamotrigine (1.44), levetiracetam (1.38), zonisamide (1.19), carbamazepine (0.54), gabapentin (0.14) and oxcarbazepine (0.0). Gabapentin reported the most fatalities (0.49 per 1,000,000 R_x). Injury, poisoning & procedural complications ADRs were suspected of association with valproic acid (31.66 per 1,000,000 R_{x} , χ^2 test, P < .05, d = 1.668, 95% CI [1.464, 1.901]), and carbamazepine (16.13 per $1,000,000 R_x$, χ^2 test, P < .05, d = 1.091, 95% CI [0.923, 1.291]). For foetal exposure during pregnancy, valproic acid was unique (d = 6.632, 95% CI [4.894, 8.988] (**Figure 1b**).

Gastrointestinal disorders

Oxcarbazepine had the most suspected gastrointestinal (GI) ADRs (20.06 per 1,000,000 R_x) with nausea and vomiting the highest within this category (14.49 per 1,000,000 R_x). Suspected fatalities due to drug-GI effects were reported for valproic acid (0.16 per 1,000,000 R_x) and levetiracetam (0.08 per 1,000,000 Rx). Gastrointestinal disorders ADRs were suspected of association with gabapentin (6.81 per 1,000,000 R_x , χ^2 test, P < .05, d = 1.881, 95% CI [1.611, 2.197]) and topiramate (19.90 per 1,000,000 R_x , χ^2 test, P < .05, d = 1.466, 95% CI [1.176, 1.827]).

General disorders and administrative site conditions

Oxcarbazepine reported the most suspected general disorders and administrative site conditions (63.83 per 1,000,000 R_x). Developmental delays were reported in valproic acid $(1.71 \text{ per } 1,000,000 R_x)$, levetiracetam (0.16) and carbamazepine (0.09). Zonisamide reported the most fatalities (2.38 per 1,000,000 R_x). General disorders and administration site conditions ADRs were suspected of association with zonisamide (51.11 per 1,000,000 R_x , χ^2 test, P < .05, d = 1.676, 95% CI [1.193, 2.353]), oxcarbazepine (63.83 per 1,000,000 R_x , χ^2 test, P < .05, d = 1.243, 95% CI [0.862, 1.792]), and gabapentin (10.06 per 1,000,000 R_x , χ^2 test, P < .05, d = 1.296, 95% CI [1.142, 1.470]).

Nervous system disorders

Oxcarbazepine reported the most ADRs for epilepsy (9.12 per 1,000,000 R_x) and seizures (29.18 per 1,000,000 R_x). Fatalities were reported in four AEDs (valproic acid, carbamazepine, gabapentin, and levetiracetam) with valproic acid having the highest rate (0.16 per 1,000,000 R_x). Nervous system disorders ADRs were suspected of association with oxcarbazepine $(96.65 \text{ per } 1,000,000 R_x, \chi^2 \text{ test}, P < .05, d = 1.387, 95\% \text{ CI } [1.014, 1.897])$, topiramate (45.63)per 1,000,000 R_x , χ^2 test, P < .05, d = 1.224, 95% CI [1.049, 1.430]), levetiracetam (29.13 per $1,000,000 R_x$, χ^2 test, P < .05, d = 1.180, 95% CI [1.039, 1.339]), and zonisamide (48.73 per 1,000,000 R_x , χ^2 test, P < .05, d = 1.035, 95% CI [0.733, 1.460]).

Psychiatric Disorders

Oxcarbazepine had the highest suspected rate of psychiatric ADRs (60.18 per 1,000,000 R_x). The size effect of these suspected psychiatric disorder ADRs were as follows: levetiracetam $(24.26 \text{ per } 1,000,000 R_x, \chi^2 \text{ test}, P < .05, d = 1.485, 95\% CI [1.294, 1.705]), gabapentin (10.22)$ per 1,000,000 R_x , χ^2 test, P < .05, d = 1.341, 95% CI [1.182, 1.520]), oxcarbazepine (60.18) per 1,000,000 R_x , χ^2 test, P < .05, d = 1.166, 95% CI [0.802, 1.695]), and topiramate (30.35) per 1,000,000 R_x , χ^2 test, P < .05, d = 1.123, 95% CI [0.936, 1.346]). Anxiety disorders and symptoms were the most reported in oxcarbazepine, zonisamide, topiramate, levetiracetam, lamotrigine, valproic acid, carbamazepine and gabapentin in a descending order. Valproic acid had the most reports for learning disorders (3.26 per 1,000,000 Rx), attention-deficit hyperactivity disorder [ADHD] (0.98 per 1,000,000 R_x) and autism spectrum disorders [ASD] $(3.17 \text{ per } 1,000,000 R_x).$

Other ADRs:

Pregnancy, Puerperium & Perinatal Conditions ADRs

Pregnancy, Puerperium & Perinatal (PPP) conditions ADRs were suspected of association with lamotrigine (1.51 per 1,000,000 R_x , χ^2 test, P < .05, d = 2.720, 95% CI [1.656, 4.469]), and valproic acid (2.28 per 1,000,000 R_x , χ^2 test, P < .05, d = 1.846, 95% CI [1.150, 2.964]). PPP ADRs include the following MedDRA terms: abortions and still births, foetal complications, neonatal and perinatal conditions, and pregnancy, labour, delivery and postpartum conditions in this study.

Respiratory, Thoracic and Mediastinal Disorders ADRs

Respiratory, thoracic, and mediastinal disorders were most reported in zonisamide (11.89 per 1,000,000 R_x). Gabapentin and valproic acid reported fatalities (both 0.08 per 1,000,000 R_x). Respiratory, Thoracic and Mediastinal Disorders ADRs were suspected of association with zonisamide (11.89 per 1,000,000 R_x , χ^2 test, P < .05, d = 1.837, 95% CI [0.964, 3.501]), carbamazepine (6.00 per 1,000,000 R_x , χ^2 test, P < .05, d = 1.478, 95% CI [1.124, 1.943]), topiramate (7.03 per 1,000,000 R_x , χ^2 test, P < .05, d = 1.305, 95% CI [0.913, 1.864]), and gabapentin (1.77 per 1,000,000 R_x , χ^2 test, P < .05, d = 1.066, 95% CI [0.809, 1.404]).

Skin and Subcutaneous Tissue Disorders ADRs

Zonisamide had the most skin and subcutaneous tissue disorder ADRs (33.28 per 1,000,000 R_{x}), with oxcarbazepine reporting the most rashes (10.94 per 1,000,000 R_{x}). No fatalities were reported. Skin and subcutaneous tissue disorders ADRs were suspected of association with lamotrigine (19.69 per 1,000,000 R_x , χ^2 test, P < .05, d = 3.014, 95% CI [2.601, 3.492]), carbamazepine (21.05 per 1,000,000 R_x , χ^2 test, P < .05, d = 1.948, 95% CI [1.665, 2.277]), and zonisamide (33.28 per 1,000,000 R_x , χ^2 test, P < .05, d = 1.811, 95% CI [1.210, 2.712]).

Discussion

The 8 AEDs have differing modes of action. Valproic acid increases GABAergic (g-aminobutyric acid) and glutamatergic neurotransmission while inhibiting neuronal sodium channels and altering cellular signalling and ERK pathways. Valproic acid is a potent first-generation antiepileptic but is known to be teratogenic and can cause liver and pancreas damage.[34-36] Carbamazepine, topiramate, lamotrigine, oxcarbazepine and zonisamide increase GABA transmission and block voltage-gated sodium channels to inhibit neuronal firing and suppress the release of excitatory amino acid glutamate. Levetiracetam causes modulation of synaptic neurotransmission release by binding to synaptic vesicle protein SV2A which can inhibit neurotransmitter release.[37] Gabapentin inhibits α -2- δ subunit of voltage-gated calcium channels resulting in glutamate release. The polypharmacology of these AEDs may explain the ADRs observed. Secondly, it is possible that either the beneficial effects or the adverse effects, perhaps both, are produced by different combinations of mechanisms, some of which are labelled "off-targets".

AEDs control seizure activity through disparate mechanisms which may elicit different ADR profiles.[38] oxcarbazepine had the most suspected ADRs (393.90 per 1,000,000 R_x) compared to gabapentin with the least (62.44). Oxcarbazepine and zonisamide are the least prescribed and newest AEDs.

It was expected that the black triangle drug, valproic acid would have the most off-target interactions based on LLE <5. Clinically achievable targeting of HDACs by valproic acid is associated with teratogenicity (HDAC 1 IC₅₀ = 54.4 μ M, HDAC2 IC₅₀ = 82.4 μ M, HDAC3 IC₅₀ = 148 μ M, HDAC8 IC₅₀ = 144 μ M, valproic acid C_{max} = 184.3 μ M). valproic acid was the only AED with an odds value >>1 for foetal exposure ((d = 6.632, 95% CI [4.894, 8.988]) and congenital and hereditary disorders (valproic acid (d = 9.069, 95% CI [5.807, 14.163]).

All ADRs

Oxcarbazepine had the most standardised reported suspected ADRs for psychiatric (60.18 per 1,000,000 R_x) and nervous system disorders (69.65). Suspected skin reactions were reported most with zonisamide, potentially linked to its ability to induce lupus through increasing anti-nucleic antibodies.[39] Valproic acid is known to cause pancreatitis and displayed the highest relative rate of exocrine pancreatic conditions (2.44 per 1,000,000 R_x).[40] Topiramate had similar standardised suspected ADRs to other AEDs, with most suspected reactions in psychiatric disorders (30.35 per 1,000,000 R_x) and nervous system (45.63). Paraesthesia, caused by inhibition of carbonic anhydrase enzymes (carbonic anhydrase I IC₅₀ = 250 nM and carbonic anhydrase II IC₅₀ = 868.3 nM vs. C_{max} = 4420 nM [topiramate]) alters nerve cell communication and/or its effects on peripheral nerve cells.[41]

Carbamazepine had suspected nervous system disorders (21.32 per 1,000,000 R_x), including neurodevelopmental disorders which may be caused by histone deacetylase targeting (HDAC3 and 7).[42] Skin disorders (21.05 per 1,000,000 R_x) may be explained by carbamazepine rapidly activating T-cells through direct interaction with major histocompatibility (MHC) proteins and specific T-cell receptors causing an immune response.[43]

Levetiracetam was suspected of nervous system (d = 1.180 [1.039-1.339]) and psychiatric disorder ADRs (d = 1.485 [1.294-1.705]) and displayed one of the higher reported seizure rates (6.09 per 1,000,000 R_x), suggesting a lower level of epilepsy control.[44]

Lamotrigine's suspected ADRs were in pregnancy or skin conditions, with lamotrigine-induced rash a well-reported side effect, with hypersensitivity from valproic acid interfering with glucuronide metabolism and increasing lamotrigine blood levels.[45] *h*ERG was targeted by lamotrigine and carbamazepine but not at levels associated with arrythmia.

Gabapentin had the lowest standardised ADRs. Gastrointestinal, psychiatric, and GI disorders were the predominant ADRs and its ability to target α -2- δ voltage-gated calcium channels inhibit neurotransmitter release but causes glutamate-induced glutamate release from astrocytes generating neurotoxicity and psychiatric symptoms.[46]

Congenital, Familial and Genetic Disorder ADRs and Neurodevelopmental ADRs

All AEDs except gabapentin reported congenital, familial, and genetic disorder ADRs with statistical significance for valproic acid (**Table S3**). Valproic acid was the only AED to display a strong association between exposure and this ADR, with d = 6.432 [4.955-8.348] (**Figure 1a**).

Foetal exposure ADR is most associated with valproic acid (**Table 2**). Valproic acid crosses the placental barrier with increasing concentrations in cord blood than maternal serum, higher doses increase foetal accumulation, increasing the pharmacological effect.[47] Studies have linked teratogenicity to direct inhibition of placental folate uptake through blocking folate receptors, specifically FOLR1. FOLR1 affects embryonic folate metabolism through inhibiting glutamate formyl transferase while increasing plasma homocysteine levels and reducing serum folate, causing placental folate deficiency which limits synthesis of purines and thymine required for DNA formation, resulting in congenital malformations.[12,48-50]

Valproic acid is suspected of causing neurodevelopmental disorder ADRs, including learning disorders (3.26 per 1,000,000 R_x), autism (3.17), developmental delay (1.71), developmental speech disorders (1.06), and ADHD (0.98). This may be linked to valproic acid's ability to inhibit HDAC2 (IC₅₀ = 82.4 μ M, C_{max} = 184.3 μ M).[42] HDAC2 inhibition affects cellular differentiation, causes apoptosis leading to congenital, and developmental disorders through histone hyperacetylation, affecting normal gene transcription.[51] *In-utero* exposure causes atrial septal defect (ASD) through transient histone hyperacetylation in the embryonic brain, increasing apoptotic cells in the neocortex and decreasing cell proliferation while altering *m*RNA levels, delaying neuronal maturation.[42]

Carbamazepine is considered teratogenic.[52] Off-target interactions with HDAC3 and 7 (both IC $_{50}$ = 2 μ M, C $_{max}$ = 11-14.8 μ M) may contribute to suspected congenital, familial and genetic disorders ADRs (1.61 per 1,000,000 R_x).[53] It disturbs cardiac rhythm secondary to its propensity to inhibit specific ion current (Ikr) and subsequent hypoxic damage as Ikr is essential for embryonic cardiac repolarisation and rhythm regulation and impairs folate absorption.[54] Topiramate has an identical suspected congenital, familial and genetic disorder ADRs profile to carbamazepine and increased congenital and neurodevelopmental disorders, risk of low birth weight and foetal growth restrictions. This is due to HDAC inhibition causing hyperacetylation in human cells at lower potency than valproic acid. Topiramate inhibits

carbonic anhydrase (I and II, IC₅₀ = 0.25 and 0.87 μ M, respectively vs. C_{max} = 4.4 μ M) which reduces embryonic intracellular pH but is required to control cellular development.[54]

Zonisamide has limited studies into pregnancy ADRs (2.38 per 1,000,000 R_x), however carbonic anhydrase inhibition (II and V, 35.2 and 20.6 nM, respectively $vs. C_{max} = 9.4 \mu M$) may cause teratogenicity. It causes low birth weight for gestational age in 21% of exposure and animal models support its teratogenic potential.[55]

Lamotrigine (2.23 per 1,000,000 R_x) and levetiracetam (1.87 per 1,000,000 R_x) had higher standardised congenital, familial, and genetic disorder ADRs than carbamazepine and topiramate (both 1.61 per 1,000,000 R_x) despite being considered safer AEDs in pregnancy.[8] Lamotrigine dual therapy (with vigabatrin) has been reported to increase neurodevelopmental risk and its effect on dihydrofolate reductase (DHFR) may be teratogenic.[54,56]

Levetiracetam's major metabolite, 2-pyrrolidinone-n-butyric acid (PBA), is an unspecified HDAC class inhibitor which can be teratogenic, however studies support a margin of reproductive safety.[57] Oxcarbazepine shows congenital malformations (1.82 per 1,000,000 R_x) but insufficient maternal exposure prevents conclusions being drawn and studies are limited into teratogenic mechanisms.[58]

Overall, suspected teratogenic effects were shown to occur with AEDs but are relatively uncommon, except for valproic acid, and can be linked to their pharmacological activity. Targeting of carbonic anhydrase or histone deacetylase can result in specific receptor-mediated teratogenesis and are the most likely causes of these ADRs occurring alongside some AED's role in folate antagonism causing foetal folate deficiency.[54] Valproic acid had the most congenital and neurodevelopmental adverse effects, potentially linked to it inhibiting the most histone deacetylase isozymes and its interference in folate metabolism.[54] Other AEDs which inhibit carbonic anhydrase included carbamazepine, topiramate and levetiracetam's active metabolite PBA - all reported congenital and neurodevelopmental adverse reactions. The teratogenic effects of lamotrigine and oxcarbazepine are unknown, however both drugs have reported congenital and neurodevelopmental ADRs. Lamotrigine, valproic acid and carbamazepine all undergo folate antagonism which is known to be a further teratogenic mechanism by inhibiting the folate methylation cycle, with carbamazepine able to impair folate absorption, lamotrigine inhibiting DHFR, and valproic acid being a folate antimetabolite.[54]

Exposure via the father

The route of exposure of a foetus to sodium valproate is highly topical at the time of this work. It is known that valproic acid can affect a foetus *in utero* by exposure via the mother during pregnancy, but it is unknown whether exposure via the father could be a potential cause of NTDs and neurological conditions. A study found that hyperacetylation of testicular histone can be linked to trans-generational genetic changes.[59] Impaired DNA methylation was linked to impaired promoter CpGs of genes which are related to brain function. This could suggest that neurological changes can be inflicted on the foetus due to modifications of the gamete. The pattern of mutations in the sperm found that many mutations were found near acetylated histone regions, suggesting valproic acid influences methylation, although not necessarily directly. The implications of these findings were changes to national guidance in the UK advising against valproic acid prescriptions in any person under 55, extending this guidance to males.[60] The FOI request (**Table S5**) identified 5 suspected reports of NTDs or

neurological abnormalities due to VPA exposure via the father since 1972. However, due to the nature of the changes, the trans-generational ADRs could be at risk of being underreported. Neurological and behavioural changes such as ASD may not present until much later in a child's development and a link to exposure to VPA as a sperm cell could plausibly be missed.

Limitations

Under-reporting of suspected ADRs prevents accurate quantification of the risks associated with AEDs.[61] Suspected ADR reporting requires no causality to be determined and co-morbidities and polypharmacy of patients is not publicly accessible information. Neurodevelopmental disorders have overlapping symptoms and can take years to be diagnosed, with adolescent and adult diagnosis common, meaning links between AED use in pregnancy may be missed.[62] Different ADRs are likely to be under-reported at widely different rates, especially teratogenic events, which are much more likely to be reported than other events, thus data reported by the UK's National Congenital Anomaly and Rare Disease Registration Service (NCARDRS) is used for comparison.[63] Some congenital defects are reported on behalf of the child and some on behalf of the mother who gave birth to the affected child. It was not possible to filter by route of exposure because some congenital defects are reported on behalf of the child (which would be trans-placental) and some on behalf of the mother (which would be oral) who gave birth to the affected child, so only searches for congenital defects which occurred in-utero was possible. A consistent, nationally implemented method of reporting ADRs is required, to have a better understanding of the clinical application of these findings, and to allow for the most effective and appropriate AED to be prescribed.

Valproic acid is more widely prescribed in men and over 55s than it is in women of childbearing age due to the restrictions in prescribing valproic acid to women, meaning the number of congenital defects as a percentage of female patients (of childbearing age) is again likely to be higher. It could be hypothesised that this would also be true when comparing valproic acid to lamotrigine and carbamazepine, two drugs without the same restrictions in prescribing to women. Lamotrigine and carbamazepine also do not have a PPP, making the data less comparable.

Due to transgenerational aspect of this data, there could be a significant degree of underreporting, especially for conditions such as ASD where symptoms do not appear until later in life. The ambiguity of valproic acid exposure via the father could further contribute to this.

OpenPrescribing gives 5-year prescribing data for England (83.9% of the UK population in mid-2021), whereas ADR data is for the UK, causing standardisation to appear higher than the true value by approximately 19.2%. This can only be an approximation as a complex set of factors influencing ADRs, including social deprivation and drug and alcohol use, vary between regions. Prescribing guidance was implemented in 2018 (the PPP) for the black triangle drug valproic acid therefore some ADR reports will include valproic acid exposure *in-utero* prior to this.

Of the eight AEDs studied, only valproate is a black-triangle drug in the UK. That suggests that suspected ADRs to valproate would have been more likely to have been reported than suspected ADRs to the other drugs, thus potentially skewing the data.

Standardisation per 1,000,000 Rx improves validity due to the need for $n \ge 5$ reports for accurate statistical analysis. Not all organ systems met ≥ 5 reported reactions required for odds ratio calculations. Incomplete pharmacological profiles would also limit potential mechanistic correlations.

Conclusion

All AEDs examined in this study have unique suspected ADR profiles. ADRs per 1,000,000 R_x identified across all AEDs are statistically significant (χ^2 test, P < .05).

Pregnancy, puerperium & perinatal conditions ADRs suspected of association with lamotrigine (1.51 per 1,000,000 R_x , χ^2 test, P < .05, d = 2.720, 95% CI [1.656, 4.469]) had a larger size effect than valproic acid (2.28 per 1,000,000 R_x , χ^2 test, P < .05, d = 1.846, 95% CI [1.150, 2.964]).

All AEDs studied except for gabapentin had teratogenic effects. With at least one reported congenital, familial, and genetic disorder ADR, primarily foetal anticonvulsant syndrome or congenital anomaly. The size effect associated with valproic acid for congenital and hereditary disorders, (d = 9.069, 95% CI [5.807, 14.163]) and foetal exposure during pregnancy, the size effect associated with valproic acid (d = 6.632, 95% CI [4.894, 8.988]) were pronounced. Valproic acid had polypharmacology including the unique and clinically achievable targeting of histone deacetylase (HDAC 1 IC₅₀ = 54.4 μ M, HDAC2 IC₅₀ = 82.4 μ M, HDAC3 IC₅₀ = 148 μ M, HDAC8 IC₅₀ = 144 μ M, C_{max} = 184.3 μ M) associated with teratogenicity.

Consideration of the paternal exposure route to valproic acid birth defects revealed five suspected reports. However, these are likely underreported clinically due to its transgenerational aspect and the delay in the appearance of behavioural/neurological symptoms the link may not be made to valproic acid exposure as a gamete.

Acknowledgements

The authors thank the MHRA Yellow Card, ChEMBL, OpenPrescribing for access to the underlying data for this study.

Data availability statements: All supporting data is freely available via the supporting information file(s).

Funding statement: No funding is linked to this study.

Author contribution statement: AMJ and VS designed the project, supervised, and drafted/revised the manuscript, BP and IE carried out the investigation and statistical analyses and drafted the manuscript.

Conflict of interest disclosure: BP, IE, VS, and AMJ have no conflicts of interest to disclose.

Ethics approval statement: The study used fully anonymised publicly available data and ethics approval was not required.

References

- [1] Osanlou R, Walker L, Hughes DA, et al. Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions BMJ Open 2022;12:e055551. Doi: 10.1136/bmjopen-2021-055551
- [2] Epilepsy Research UK, Epilepsy Statistics, [internet]. 2019 [cited 2022 December 07]. Available from: https://epilepsyresearch.org.uk/about-epilepsy/epilepsy-statistics/
- [3] Epilepsy medicines and pregnancy, Medicines, and Healthcare products regulatory agency. [internet] 2021 [cited 2022 December 07]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/950069/Epilepsy-medicines-in-pregnancy-leaflet.pdf
- [4] Christensen J, Vestergaard C, Hammer Bech B. Maternal death in women with epilepsy. Neurology. 2018 Oct 30;91(18):e1716–20.
- [5] Speidel BD, Meadow SR. MATERNAL EPILEPSY AND ABNORMALITIES OF THE FETUS AND NEWBORN. The Lancet. 1972 Oct 21;300(7782):839–43.
- [6] Sodium Valproate Timeline Key Events, The Independent Medicines, and Medical Devices Safety Review. [internet] 2020 [cited 2022 December 08]. Available from: https://www.immdsreview.org.uk/downloads/Annexes/Annex-C-Valproate-timeline.pdf
- [7] CPRD STUDY MONITORING THE USE OF VALPROATE IN GIRLS AND WOMEN IN THE UK: January 2010 to December 2019
- [8] Clayton-Smith J, Bromley R, Dean J, Journel H, Odent S, Wood A, et al. Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability. Orphanet J Rare Dis. 2019 Jul 19;14:180.
- [9] Cummings C, Stewart M, Stevenson M, Morrow J, Nelson J. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child. 2011 Jul 1;96(7):643–7.
- [10] Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, et al. Cognitive Function at 3 Years of Age after Fetal Exposure to Antiepileptic Drugs. N Engl J Med. 2009 Apr 16;360(16):1597–605.
- [11] Koren G, Nava-Ocampo AA, Moretti ME, Sussman R, Nulman I. Major malformations with valproic acid. Can Fam Physician. 2006 Apr;52(4):441-2, 444, 447.
- [12] Macfarlane A, Greenhalgh T. Sodium valproate in pregnancy: what are the risks, and should we use a shared decision-making approach? BMC Pregnancy Childbirth 2018 18:200.
- [13] Ranjith S, Abhishek J. Measures to Mitigate Sodium Valproate Use in Pregnant Women with Epilepsy. Cureus 2022 14:e30144.
- [14] Mahase E. Sodium valproate continues to be prescribed in hundreds of pregnancies, data show. BMJ 2022 377:o1013.
- [15] Eriksson SH, Tittensor P, Sisodiya SM. National compliance with UK wide guidelines for usage of valproate in women of childbearing potential. Seizure. 2022 May;98:8-12. Doi: 10.1016/j.seizure.2022.03.020. Epub 2022 Mar 30.
- [16] Cumberlege J. First Do No Harm The report of the Independent Medicines and Medical Devices Safety Review, [Internet]. [cited 2024 Jan 2]. https://www.immdsreview.org.uk/downloads/IMMDSReview_Web.pdf
- [17] Giri VP, Giri OP, Khan FA, Kumar N, Kumar A, Haque A. Valproic Acid versus Lamotrigine as First-line Monotherapy in Newly Diagnosed Idiopathic Generalized Tonic -Clonic Seizures in Adults A Randomized Controlled Trial. J Clin Diagn Res. 2016 Jul;10(7):FC01-4. Doi: 10.7860/JCDR/2016/16911.8121. Epub 2016 Jul 1.
- [18] Thangaratinam S, Marlin N, Newton S, et al. AntiEpileptic drug Monitoring in PREgnancy (EMPiRE): a double-blind randomised trial on effectiveness and acceptability of monitoring strategies. Southampton (UK): NIHR Journals Library; 2018 May. (Health Technology Assessment, No. 22.23.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK499526/ doi: 10.3310/hta22230
- [19] Bjørk MH, Zoega H, Leinonen MK, Cohen JM, Dreier JW, Furu K, et al. Association of Prenatal Exposure to Antiseizure Medication with Risk of Autism and Intellectual Disability. JAMA Neurol. 2022;79(7):672–81.
- [20] Belete D, Jacobs BM, Simonet C, et a. Association between antiepileptic drugs and incident Parkinson disease in the UK Biobank. *JAMA Neurol.* Published online December 27, 2022. Doi:10.1001/jamaneurol.2022.4699
- [21] Yousaf, H., Jones, A.M. The Relationship Between Suspected Adverse Drug Reactions Of HMG-Coa Reductase Inhibitors And Polypharmacology Using A National Registry Approach, Pharmacy, **2024**, *submitted*.
- [22] Jones, L., Jones, A. M. "Suspected Adverse Drug Reactions of the Type 2 Antidiabetic Drug class Dipeptidy-Peptidase IV inhbitors (DPP4i): Can polypharmacology help explain? medRxiv 2022.06.30.22277085; doi: https://doi.org/10.1101/2022.06.30.22277085 and Pharmacol. Res. Perspect. 2022, 10(6) e01029. https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1002/prp2.1029
- [23] Salim, H, Jones, A.M. "Angiotensin II Receptor Blockers (ARBs) and Manufacturing Contamination: A Retrospective National Register Study into suspected associated adverse drug reactions" Brit. J. Clin. Pharmacol. 2022, 88(11), 4812-4827. Doi: 10.1111/bcp.15411 https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.15411

- [24] Sandhu, D., Antolin, A.A., Cox, A. R., Jones, A.M. "Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale". Brit. J. Clin. Pharmacol. 2022, 88, 742-752. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15015
- [25] Matharu, K., Chana, K., Ferro, C., Jones, A. M. "Polypharmacology of clinical sodium glucose co-transport protein 2 inhibitors and relationship to suspected adverse drug reactions." *Pharmacol. Res. Perspect.* **2021**, *9*, e00867. https://bpspubs.onlinelibrary.wiley.com/doi/10.1002/prp2.867
- [26] Ferro, C. J., Solkhon, F., Jalal, Z., Al-Hamid, A. M., Jones, A. M. "Relevance of physicochemical properties and functional pharmacology data to predict the clinical safety profile of direct oral anticoagulants" *Pharmacol. Res. Perspect.* **2020**, 8, e00603. https://bpspubs.onlinelibrary.wiley.com/doi/10.1002/prp2.603
- [27] Hann M. Molecular obesity, potency, and other addictions in drug discovery. MedChemComm. 2011; 2(5):349-55.
- [28] Subramanian S, Bates SE, Wright JJ, Espinoza-Delgado I, Piekarz RL. Clinical Toxicities of Histone Deacetylase Inhibitors. Pharmaceuticals (Basel). 2010 Aug 26;3(9):2751-2767. Doi: 10.3390/ph3092751.
- [29] Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001 Sep 28;276(39):36734-41. Doi: 10.1074/jbc.M101287200. Epub 2001 Jul 25.
- [30] Kultima, K., Nyström, A.-M., Scholz, B., Gustafson, A.-L., Dencker, L., & Stigson, M. (2004). Valproic Acid Teratogenicity: A Toxicogenomics Approach. *Environmental Health Perspectives*, 112(12), 1225–1235. http://www.jstor.org/stable/3838123
- [31] Alfonso Lampen, Paul A. Grimaldi and Heinz Nau, Modulation of Peroxisome Proliferator-Activated Receptor δ Activity Affects Neural Cell Adhesion Molecule and Polysialyltransferase ST8SialV Induction by Teratogenic Valproic Acid Analogs in F9 Cell Differentiation, Molecular Pharmacology July 1, 2005, 68 (1) 193-203; DOI: https://doi.org/10.1124/mol.104.009340
- [32] Gurvich N, Berman MG, Wittner BS, Gentleman RC, Klein PS, Green JB. Association of valproate-induced teratogenesis with histone deacetylase inhibition in vivo. FASEB J. 2005 Jul;19(9):1166-8. Doi: 10.1096/fj.04-3425fje. Epub 2005 May 18.
- [33] Tanoshima M, Kobayashi T, Tanoshima R, Beyene J, Koren G, Ito S. Risks of congenital malformations in offspring exposed to valproic acid in utero: A systematic review and cumulative meta-analysis. Clin Pharmacol Ther. 2015 Oct;98(4):417-41. Doi: 10.1002/cpt.158. Epub 2015 Aug 10.
- [34] Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK, et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2013 Apr;23(4):236–41.
- [35] Romoli M, Mazzocchetti P, D'Alonzo R, Siliquini S, Rinaldi VE, Verrotti A, et al. Valproic acid and Epilepsy: From Molecular Mechanisms to Clinical Evidence. Curr Neuropharmacol. 2019 Oct;17(10):926–46.
- [36] Wiltse J. Mode of action: inhibition of histone deacetylase, altering WNT-dependent gene expression, and regulation of beta-catenin—developmental effects of valproic acid. Crit Rev Toxicol. 2005;35(8–9):727–38.
- [37] Abou-Khalil B. Levetiracetam in the treatment of epilepsy. Neuropsychiatry Dis Treat. 2008 4(3):507-23
- [38] Sills GJ, Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 2020; 168:107966.
- [39] Safadi MG, Smith K, Hassan S, Patel V, Viglione M, Zahner SL. Probable drug-induced lupus erythematosus by zonisamide. JAAD Case Rep. 2021; 17:4–6.
- [40] Ray S, Khamrui S, Kataria M, Biswas J, Saha S. Valproic acid-Induced Severe Acute Pancreatitis with Pseudocyst Formation: Report of a Case. Cureus. 2015 Aug 8;7(8):e297
- [41] Hamed SA. Topiramate induced peripheral neuropathy: A case report and review of literature. World J Clin Cases. 2017; 5(12):446–52.
- [42] Kawanai T, Ago Y, Watanabe R, Inoue A, Taruta A, Onaka Y, et al. Prenatal Exposure to Histone Deacetylase Inhibitors Affects Gene Expression of Autism-Related Molecules and Delays Neuronal Maturation. Neurochem Res. 2016; 41(10):2574–84
- [43] Wu Y, Sanderson JP, Farrell J, Drummond NS, Hanson A, Bowkett E, et al. Activation of T cells by carbamazepine and carbamazepine metabolites. J Allergy Clin Immunol. 2006; 118(1):233–41.
- [44] Abou-Khalil B. Levetiracetam in the treatment of epilepsy. Neuropsychiatr Dis Treat. 2008; 4(3):507–23.
- [45] Parveen S, Javed MA. Stevens Johnson Syndrome associated with Lamotrigine. Pak J Med Sci. 2013;29(6):1450-2.
- [46] Evrensel, A., & Ünsalver, B. Ö. (2015). Psychotic and depressive symptoms after gabapentin treatment. The International Journal of Psychiatry in Medicine, 49(4), 245–248. https://doi.org/10.1177/0091217415589295
- [47] Bank AM, Stowe ZN, Newport DJ, Ritchie JC, Pennell PB. Placental passage of antiepileptic drugs at delivery and neonatal outcomes. Epilepsia. 2017; 58(5):e82–6.
- [48] Rubinchik-Stern M, Shmuel M, Bar J, Kovo M, Eyal S. Adverse placental effects of valproic acid: Studies in perfused human placentas. Epilepsia. 2018;59(5):993–1003.

- [49] Revnolds EH. Green R. Valproate and folate: Congenital and developmental risks, Epilepsy Behav, 2020; 108:107068.
- [50] Morrell MJ. Folic Acid and Epilepsy. Epilepsy Curr. 2002; 2(2):31-4.
- [51] Giavini E, Menegola E. Teratogenic activity of HDAC inhibitors. Curr Pharm Des. 2014;20(34):5438-42.
- [52] Matalon S, Schechtman S, Goldzweig G, Ornoy A. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol. 2002 Jan-Feb;16(1):9-17. doi: 10.1016/s0890-6238(01)00199-x.
- [53] Nie Q, Su B, Wei J. Neurological teratogenic effects of antiepileptic drugs during pregnancy (Review). Exp Ther Med. 2016; 12(4):2400-4.
- [54] van Gelder MMHJ, van Rooij IALM, Miller RK, Zielhuis GA, de Jong-van den Berg LTW, Roeleveld N. Teratogenic mechanisms of medical drugs. Hum Reprod Update. 2010; 16(4):378-94
- [55] McCluskey G, Kinney MO, Russell A, Smithson WH, Parsons L, Morrison PJ, et al. Zonisamide safety in pregnancy: Data from the UK and Ireland epilepsy and pregnancy register. Seizure, 2021: 91:311-5.
- [56] Shamshad H, Bakri R, Mirza AZ. Dihydrofolate reductase, thymidylate synthase, and serine hydroxy methyltransferase: successful targets against some infectious diseases. Mol Biol Rep. 2022 49(7): 6659-6691.
- [57] Isoherranen N, Spiegelstein O, Bialer M, Zhang J, Merriweather M, Yagen B, et al. Developmental Outcome of Levetiracetam, Its Major Metabolite in Humans, 2-Pyrrolidinone N-Butyric Acid, and Its Enantiomer (R)-α-ethyl-oxo-pyrrolidine Acetamide in a Mouse Model of Teratogenicity. Epilepsia. 2003;44(10):1280-8.
- [58] Montouris G. Safety of the newer antiepileptic drug oxcarbazepine during pregnancy. Curr Med Res Opin. 2005; 21(5):693-701.
- [59] K; SKK. Testicular histone hyperacetylation in mice by valproic acid administration affects the next generation by changes in sperm DNA methylation [Internet]. U.S. National Library of Medicine; 2023 [cited 2024 Jan 2]. Available from: https://pubmed.ncbi.nlm.nih.gov/36893188/
- [60] Valproate: Review of Safety Data and expert advice on... gov.uk [Internet]. 2023 [cited 2024 Jan 2]. Available from: https://assets.publishing.service.gov.uk/media/65660310312f400013e5d508/Valproate-report-review-and-expert-advice.pdf
- [61] Hazell L, Shakir SAW. Under-Reporting of Adverse Drug Reactions. Drug Saf. 2006; 29(5):385-96.
- [62] Russell G, Stapley S, Newlove-Delgado T, Salmon A, White R, Warren F, et al. Time trends in autism diagnosis over 20 years: a UK population-based cohort study. J Child Psychol Psychiatry. 2022; 63(6):674-82.
- [63] https://digital.nhs.uk/ndrs/about/ncardrs [accessed 25.03.2024]